Valuation: Elicio Therapeutics, Inc.

Market Cap 53.88M 46.42M 43.95M 39.84M 74.74M 5.15B 75.12M 522M 201M 2.62B 202M 198M 8.27B P/E 2026 *
-1.06x
P/E 2027 * -0.95x
Enterprise Value 53.88M 46.42M 43.95M 39.84M 74.74M 5.15B 75.12M 522M 201M 2.62B 202M 198M 8.27B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
72.98%
Yield 2026 *
-
Yield 2027 * -
1 day-2.84%
1 week-14.94%
Current month-24.07%
1 month-34.92%
3 months-86.20%
6 months-83.20%
Current year-74.25%
1 week 2.02
Extreme 2.02
2.46
1 month 2.02
Extreme 2.02
3.36
Current year 2.02
Extreme 2.02
16
1 year 2.02
Extreme 2.02
16
3 years 2.02
Extreme 2.02
16
5 years 2.02
Extreme 2.02
24.39
10 years 2.02
Extreme 2.02
24.39
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2018
Director of Finance/CFO 54 24/03/2025
Chief Tech/Sci/R&D Officer - 19/11/2025
Director TitleAgeSince
Director/Board Member 66 01/10/2018
Director/Board Member 54 01/06/2023
Chairman 71 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Free

Director

21,750 0.0828%
31/8/26 Free

Director

21,750 0.0828%
31/8/26 Free

Director

21,750 0.0828%
Change 5-day change 1-year change 3-year change Capi.($)
-2.84%-14.94%-82.17%-77.52% 53.88M
+1.24%-4.25%-1.90%+9.71% 45.48B
+0.21%-2.98%+337.74%+520.30% 43.68B
+1.74%-2.24%+39.82%+20.85% 43.09B
+1.38%-3.28%+6.84%+73.19% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+108.58% 16.4B
+2.94%+1.65%+15.38%+32.04% 14.24B
+1.93%-3.55%+82.00%+36.66% 13.28B
Average +0.68%-4.37%+47.38%+84.84% 26.48B
Weighted average by Cap. +0.92%-3.50%+75.00%+124.98%

Financials

2026 *2027 *
Net sales - -
Net income -43.19M -37.21M -35.24M -31.94M -59.92M -4.13B -60.22M -418M -161M -2.1B -162M -159M -6.63B -60.71M -52.31M -49.53M -44.89M -84.22M -5.8B -84.65M -588M -226M -2.95B -228M -223M -9.32B
Net Debt - -
Logo Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Employees
33
Date Price Change Volume
11/09/26 USD 2.050 -2.84% 445,797
10/09/26 USD 2.110 -3.21% 343,241
09/09/26 USD 2.180 -7.23% 459,078
08/09/26 USD 2.350 -2.49% 324,720
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.050USD
Average target price
16.50USD
Spread / Average Target
+704.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!